{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T10:42:33Z","timestamp":1751020953000,"version":"3.28.0"},"reference-count":18,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Two trials were performed to evaluate the effect of renal and hepatic impairment on the pharmacokinetics of pritelivir and its metabolites. The renal impairment trial included subjects with mild, moderate, and severe impairment, while the hepatic impairment trial included subjects with moderate impairment. Both trials recruited a matched control group of healthy subjects. Following a single oral dose of 100\u00a0mg of pritelivir, mild and moderate renal impairment and moderate hepatic impairment did not have a clinically relevant effect on the pharmacokinetics of pritelivir. In subjects with severe renal impairment, pritelivir exposure (area under the plasma concentration\u2010time curve from time 0 to infinity (AUC<jats:sub>0\u2010<\/jats:sub><jats:sub>inf<\/jats:sub>) was 57% higher compared with controls. Pritelivir plasma protein binding was similar in subjects and controls with renal impairment, while the free fraction was higher in subjects with moderate hepatic impairment, increasing unbound pritelivir exposure by 23%. For the metabolites pyridinyl phenyl acetic acid (PPA), amino thiazole sulfonamide (ATS), and PPA\u2010acyl glucuronide, generally higher exposure was observed with increasing degree of renal impairment (ie, moderate to severe), but not with mild impairment. A modest effect of moderate hepatic impairment was observed for PPA and ATS. Pritelivir was safe and well tolerated in healthy subjects and subjects with renal or hepatic impairment.<\/jats:p>","DOI":"10.1002\/cpdd.1469","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T07:47:47Z","timestamp":1727250467000},"page":"1198-1211","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Pritelivir and Its Metabolites"],"prefix":"10.1002","volume":"13","author":[{"given":"Katharina","family":"Erb\u2010Zohar","sequence":"first","affiliation":[{"name":"clinphase\u00ae  Schotten Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Bonsmann","sequence":"additional","affiliation":[{"name":"AiCuris Anti\u2010infective Cures AG  Wuppertal Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Pausch","sequence":"additional","affiliation":[{"name":"Affiliation at time of the studies: Aicuris Anti\u2010infective Cures AG  Wuppertal Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Sumner","sequence":"additional","affiliation":[{"name":"AiCuris Anti\u2010infective Cures AG  Wuppertal Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Birkmann","sequence":"additional","affiliation":[{"name":"AiCuris Anti\u2010infective Cures AG  Wuppertal Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"AiCuris Anti\u2010infective Cures AG  Wuppertal Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atef","family":"Halabi","sequence":"additional","affiliation":[{"name":"CRS Clinical Research Services Kiel GmbH  Kiel Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Kropeit","sequence":"additional","affiliation":[{"name":"AiCuris Anti\u2010infective Cures AG  Wuppertal Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,9,25]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.13.192"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00668"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.08.024"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02641-14"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1766-1772.2002"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/095632020701800104"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.18189"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1301150"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1241"},{"issue":"4","key":"e_1_2_8_11_1","first-page":"389","article-title":"Evaluation of the clinical drug\u2010drug interaction potential of pritelivir on transporters and CYP450 enzymes using a cocktail approach","volume":"13","author":"Vries M","year":"2024","journal-title":"Clin Pharmacol Drug Dev"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1358"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"issue":"5","key":"e_1_2_8_14_1","first-page":"303","article-title":"A formula to estimate the approximate surface area if height and weight be known. 1916","volume":"5","author":"Du Bois D","year":"1989","journal-title":"Nutrition"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13061"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800600817"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13428"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197602052940605"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1982.tb02671.x"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1469","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T04:26:14Z","timestamp":1730780774000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,25]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1002\/cpdd.1469"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1469","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"type":"print","value":"2160-763X"},{"type":"electronic","value":"2160-7648"}],"subject":[],"published":{"date-parts":[[2024,9,25]]},"assertion":[{"value":"2024-03-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}